Prenoxdiazine (marketed under the brand name Libexin) is a pharmaceutical drug classified as a cough suppressant (antitussive). It is listed on the World Health Organization's Anatomical Therapeutic Chemical (ATC) classification system under code R05DB18.
Mechanism of Action
Prenoxdiazine acts peripherally by desensitizing the pulmonary stretch receptors in the respiratory tract. This reduces the frequency and intensity of cough impulses originating in the lungs, thereby suppressing non-productive (dry) cough.
Indications
Prenoxdiazine is indicated for the symptomatic relief of dry cough of bronchial origin, including cough associated with acute respiratory viral infections, bronchitis, pharyngitis, and asthma. It is typically used for short-term treatment until symptoms resolve.
Contraindications
The drug should not be used in patients with hypersensitivity to prenoxdiazine or in individuals with bronchial secretions (productive cough). Caution is advised in elderly patients, infants, and pregnant or breastfeeding women.
Adverse Effects
Common side effects include nausea, constipation, dry mouth, and allergic skin reactions. Most side effects are mild and resolve without medical intervention.
Dosage and Administration
Prenoxdiazine is administered orally, typically in doses of 100 mg or 200 mg tablets, taken in three divided doses as directed by a physician.
Chemical Properties
- IUPAC name: 1-[2-[3-(2,2-diphenylethyl)-1,2,4-oxadiazol-5-yl]ethyl]piperidine
- Molecular formula: C23H27N3O
- Molar mass: 361.489 g·mol⁻¹
- CAS number: 47543-65-7 (base); 982-43-4 (hydrochloride)
- UNII: S491HH391H (base); 390WW7V7MZ (hydrochloride)
Available Forms
Prenoxdiazine is available as the base or as the hydrochloride salt. Trade names include Libexin, Prenoxid, Tibexin, Lomapect, and Libeksin. It is marketed in several countries, including India and parts of Europe, but may not be approved in all jurisdictions.
